 Zacks Investment Research upgraded shares of Homology Medicines NASDAQ:FIXX from a hold rating to a buy rating in a report published on Tuesday, Zacks.com reports. The firm currently has 17.00 price target on the stock. According to Zacks, Homology Medicines Inc. is a genetic medicines company. Its platform offers human hematopoietic stem cell derived adeno-associated ... 